Bristol-Myers Squibb Co [BMY] stock is trading at $47.00, down -1.82%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BMY shares have gain 6.53% over the last week, with a monthly amount drifted -5.66%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Cantor Fitzgerald started tracking the stock with Neutral rating on April 22, 2025, and set its price target to $55. On December 16, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $70 on the stock. Wolfe Research initiated its recommendation with a Peer Perform. Daiwa Securities upgraded its rating to Outperform for this stock on November 13, 2024. In a note dated November 12, 2024, Leerink Partners upgraded an Outperform rating on this stock but restated the target price of $73.
Bristol-Myers Squibb Co [BMY] stock has fluctuated between $39.35 and $63.33 over the past year. Currently, Wall Street analysts expect the stock to reach $66.5 within the next 12 months. Bristol-Myers Squibb Co [NYSE: BMY] shares were valued at $47.00 at the most recent close of the market. An investor can expect a potential return of 41.49% based on the average BMY price forecast.
Analyzing the BMY fundamentals
Bristol-Myers Squibb Co [NYSE:BMY] reported sales of 47.64B for the trailing twelve months, which represents a drop of -5.60%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.13%, and Net Profit Margin reading is 0.11%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.32 and Total Capital is 0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.95.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Bristol-Myers Squibb Co’s Current Ratio is 1.28. Further, the Quick Ratio stands at 1.17, while the Cash Ratio is 0.45. Considering the valuation of this stock, the price to sales ratio is 2.01, the price to book ratio is 5.50 and price to earnings (TTM) ratio is 17.65.
Transactions by insiders
Recent insider trading involved Hickey Benjamin, President, RayzeBio Org., that happened on May 09 ’25 when 97.0 shares were sold. EVP,Chief Med.Offr.,Drug Dev., Hirawat Samit completed a deal on Apr 25 ’25 to buy 4250.0 shares. Meanwhile, Chief Executive Officer BOERNER CHRISTOPHER S. bought 2000.0 shares on Feb 20 ’25.
